VIDEO: ‘No difference’ between ustekinumab, tofacitinib for steroid-free remission in UC

CHARLOTTE, N.C. — In a Healio video exclusive, Rahul Dalal, MD, MPH, reported ustekinumab and tofacitinib yielded similar safety and efficacy in the treatment of a small subset of adult patients with ulcerative colitis.Specifically, among 97 patients who received ustekinumab (Stelara, Janssen) and 69 patients who received tofacitinib (Xeljanz, Pfizer), 48.9% and 56.1% achieved steroid-free clinical remission at 52 weeks with similar drug survival between groups (adjusted HR = 1.26; 95% CI, 0.74-2.15).Dalal, an IBD fellow at Brigham and Women’s Hospital, noted these resultsRead More

Generated by Feedzy